期刊文献+

Use of MLC901 in cerebral venous sinus thrombosis:Three case reports

下载PDF
导出
摘要 BACKGROUND Cerebral venous sinus thrombosis(CVT)is rare cause of cerebrovascular disease.The incidence is 0.5%of all stroke.The majority of affected patients are young adults(mean age:35-40 years)with mild to moderate disabilities.Poor outcome with severe disability is seen in 13%of cases.Early diagnosis and treatment are important for good outcomes and preventing complications.Treatment options are limited and mostly based on consensus.NeuroAiD II™(MLC901;Moleac Pte,Ltd,Singapore)has a potential beneficial role in post-stroke recovery,by aiding the natural brain recovery process.CASE SUMMARY MLC901 consists of nine natural herbal ingredients.Studies have shown its safety profile and aid in post stroke recovery.The aim of this case series was to demonstrate the potential role of MLC901 in stroke recovery of patients with cerebral venous sinus thrombosis(CVST)who received MLC901 in addition to standard of care.The prescribed dose of MLC901 is 400 mg/cap two capsules,three times a day.Data from these patients were prospectively collected at baseline and at monthly visits,for a duration of 3 mo.Outcome measures included adherence to therapy,side effects,National Institutes of Health Stroke Scale,Glasgow Coma Scale,modified Rankin Scale,and the Short Orientation-Memory-Concentration Test.MLC901 was well tolerated and no side effects were reported.All patients were stable with improved condition.CONCLUSION This case series highlights the potential therapeutic effects of MLC901 on CVST and provides support for further studies.
出处 《World Journal of Clinical Cases》 SCIE 2024年第2期346-353,共8页 世界临床病例杂志
  • 相关文献

参考文献1

二级参考文献11

  • 1Bavarsad shahripour R, Donnan GA. The long-term management of stroke. In: Norrving B, ed. Oxford textbook of stroke and cerebrovascular disease. 1 ed. USA: Oxford University Press; 2014:243-254.
  • 2Bavarsad shahripour R, Alexandrov AV. Ancillary approaches to plasminogen activators. Ann NY Acad Sci 2012;1268:113-119.
  • 3Bavasard Shahripour R, Shamsaei G, Pakdaman H, Majdinasab N, Nejad EM, Sajedi SA, et al. The effect ofNeuroAiD (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory. Eur J Intern Med 2011 ;22:509-513.
  • 4Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widman C, et al. MLC901, a traditinal Chinese medicine protects the brain against global ischemia. Neuropharmacology 2011 ;61:622-631.
  • 5Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 2010;58:987-1001.
  • 6Venketasubramanian N, Chen CL, Gan RN, Chan BP, Chang HM, Tan SB, et al. A double-blind, placebo- controlled, randomized, multicentre study to investigate Chinese medicine NeuroAiD efficacy on stroke recovery (CHIMES Study). Int J Stroke 2009;4:54-60.
  • 7Siow CHC. Neuroaid in stroke recovery. Eur Neurol 2008;60:264-266.
  • 8Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BPL, et al. Danqi Piantang Jiaonang (D J), a traditional Chinese medicine, in poststroke recovery. Stroke 2009:40:859-863.
  • 9Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double- blind, placebo-controlled clinical trial. Stroke Res Treatment 2011 ;2011:721613.
  • 10Gan R, Lambert C, Lianting J, Chan ESY, Venketasubramanian N, Chen C, et al. Danqi Piantang Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis 2008;25:450-456.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部